Retina

VG901 is designed to deliver a functional CNGA1 gene to retinal photoceptor target cells in patients diagnosed with retinitis pigmentosa.

The Phase 3 study will have a sample size of 150 participants—one arm of 75 participants with the RHO gene mutation and the other arm with 75 participants that are gene agnostic.

Investigators wanted to determine why patients who have retinal diseases such as diabetic retinopathy (DR) or age-related macular degeneration (AMD) can undergo cataract surgeries without experiencing a worsening of their retinal disease, while some patients do.

According to the company, MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events.

Patients can experience solar retinopathy after viewing the eclipse without protection, but it also can occur from outdoor activities, including those mentioned. It can lead to symptoms that include blurry vision, vision loss at the center of a patient’s sight and eye pain.

The effort led to the creation of an artificial vitreous body for treating retinal detachment. This solution is based on a natural carbohydrate derived from algae.

Stargardt disease is the most common inherited retinal dystrophy (causing blurring or loss of central vision) in both adults and children.

The new cohort will add patients living with IRDs caused by mutations in multiple genes to the already existing cohort of patients with IRDs caused by single gene mutations.

In a recent study led by Steven Pittler, PhD, and his team at the University of Alabama Birmingham (UAB), the role of modifier genes in retinitis pigmentosa type 59 (RP59) was meticulously examined.

Solar retinopathy is caused by prolonged or high intensity exposure of the fovea centralis to light energy. Suspected cases of solar retinopathy may require urgent referral to an ophthalmologist for diagnosis, and to eliminate treatable causes for central visual disturbance.

Electrophysiologic testing combined with structural imaging to zero in on issues.

NR1D1 and NR2E3 orphan nuclear receptors were found to have low levels of expression in patients with advanced retinoblastoma.

The trial evaluated nesvategrast (OTT166 5%) eye drops in patients with diabetic retinopathy.

The organization aims to educate viewers of dangers and safety precautions ahead of the eclipses.

The supplement is specifically crafted to promote healthy intraocular pressure (IOP), nurturing the well-being of retinal ganglion cells, and sustain the health of the retinal nerve fiber layer while boosting memory and concentration.

Stargardt disease is an orphan blindness disease that affects approximately 35,000 people in the United States.

According to the company, its proprietary non-viral gene therapy platform with minimally invasive delivery technology is providing long lasting gene expression and favorable distribution in the retina.

According to the company, 2,500 clinical and peer-reviewed studies that span 235 disease states have demonstrated the clinical utility of Optos technology.

Prevent Blindness is offering a variety of free educational resources to the public and professionals

Researchers have found that the interactive release of anti-inflammatory drugs depend on the level of retinal degeneration. A customized treatment approach is expected to be developed to reduce patients’ inconvenience of having multiple shots.

Structural and vascular changes detected in RVO-affected eyes and unaffected fellow eyes

Increased levels of p-tau181 and p-tau127 and a decreasing cerebrospinal fluid Aβ42/40 ratio better defines progression from preclinical to manifest Alzheimer’s disease.

AI matched and outshone human specialists.

The platform streamlines clinical decision workflows, management of teleophthalmology, referral decisions and patient management while improving clinic efficiencies.

Physicians offer pearls for the treatment of patients diagnosed with these diseases

Sruthi Arepalli, MD, discusses the case of a patient with syphilis and sheds light on the complexities of diagnosing a masquerading syndrome.

The free, online event will feature presentations from Rachel Huckfeldt, MD, PhD, and Rachelle Lin, OD.

To speed care, Mount Sinai’s Department of Ophthalmology launched an Eye Stroke Service and developed a treatment protocol for patients.

According to the organization, GYROS results will help researchers design clinical trials for an emerging gyrate atrophy gene therapy.